Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study
Recently, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been very often used in subjects with type 2 diabetes mellitus (T2DM). In addition, combination drugs of both inhibitors have attracted much attention in aspects of its cost-effectiveness a...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2020/4861681 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561588690747392 |
|---|---|
| author | Yoshiro Fushimi Atsushi Obata Junpei Sanada Yuichiro Iwamoto Akiko Mashiko Megumi Horiya Akiko Mizoguchi-Tomita Momoyo Nishioka Yuki Kan Tomoe Kinoshita Seizo Okauchi Hidenori Hirukawa Kenji Kohara Fuminori Tatsumi Masashi Shimoda Shuhei Nakanishi Tomoatsu Mune Kohei Kaku Hideaki Kaneto |
| author_facet | Yoshiro Fushimi Atsushi Obata Junpei Sanada Yuichiro Iwamoto Akiko Mashiko Megumi Horiya Akiko Mizoguchi-Tomita Momoyo Nishioka Yuki Kan Tomoe Kinoshita Seizo Okauchi Hidenori Hirukawa Kenji Kohara Fuminori Tatsumi Masashi Shimoda Shuhei Nakanishi Tomoatsu Mune Kohei Kaku Hideaki Kaneto |
| author_sort | Yoshiro Fushimi |
| collection | DOAJ |
| description | Recently, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been very often used in subjects with type 2 diabetes mellitus (T2DM). In addition, combination drugs of both inhibitors have attracted much attention in aspects of its cost-effectiveness and improvement of patients’ adherence. However, it is still poorly understood which factors are related to the efficacy of SGLT2 inhibitors as add-on therapy to DPP-4 inhibitors. Therefore, we aimed to elucidate in which type of individuals and/or under which conditions canagliflozin as add-on therapy to teneligliptin could exert more beneficial effects on glycemic control and/or renal protection. We retrospectively analyzed 56 Japanese subjects with T2DM in the real-world clinical practice. Three months after starting the combination therapy, the change of HbA1c (ΔHbA1c) was strongly related to HbA1c levels at baseline. As expected, serum glucagon level was increased after starting the combination therapy. Interestingly, however, the change of glucagon levels (Δglucagon) was not related to HbA1c levels at baseline, ΔHbA1c, and other parameters, which indicated that the increase of glucagon did not clinically affect the effectiveness of combination therapy. In addition, the change of urinary albumin excretion (ΔUAE) was negatively correlated with systolic blood pressure and HbA1c levels at baseline and positively correlated with the change of systolic blood pressure (ΔsBP) in univariate analysis. Furthermore, in multivariate analysis, only ΔsBP was the independent factor associated with ΔUAE. Taken together, canagliflozin as add-on therapy to teneligliptin improves glycemic control in a Δglucagon-independent manner and reduces UAE in a ΔsBP-dependent manner in Japanese subjects with T2DM. |
| format | Article |
| id | doaj-art-b9085e91888345429971ac6111e24865 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-b9085e91888345429971ac6111e248652025-02-03T01:24:39ZengWileyJournal of Diabetes Research2314-67452314-67532020-01-01202010.1155/2020/48616814861681Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective StudyYoshiro Fushimi0Atsushi Obata1Junpei Sanada2Yuichiro Iwamoto3Akiko Mashiko4Megumi Horiya5Akiko Mizoguchi-Tomita6Momoyo Nishioka7Yuki Kan8Tomoe Kinoshita9Seizo Okauchi10Hidenori Hirukawa11Kenji Kohara12Fuminori Tatsumi13Masashi Shimoda14Shuhei Nakanishi15Tomoatsu Mune16Kohei Kaku17Hideaki Kaneto18Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, JapanRecently, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium-glucose cotransporter 2 (SGLT2) inhibitors have been very often used in subjects with type 2 diabetes mellitus (T2DM). In addition, combination drugs of both inhibitors have attracted much attention in aspects of its cost-effectiveness and improvement of patients’ adherence. However, it is still poorly understood which factors are related to the efficacy of SGLT2 inhibitors as add-on therapy to DPP-4 inhibitors. Therefore, we aimed to elucidate in which type of individuals and/or under which conditions canagliflozin as add-on therapy to teneligliptin could exert more beneficial effects on glycemic control and/or renal protection. We retrospectively analyzed 56 Japanese subjects with T2DM in the real-world clinical practice. Three months after starting the combination therapy, the change of HbA1c (ΔHbA1c) was strongly related to HbA1c levels at baseline. As expected, serum glucagon level was increased after starting the combination therapy. Interestingly, however, the change of glucagon levels (Δglucagon) was not related to HbA1c levels at baseline, ΔHbA1c, and other parameters, which indicated that the increase of glucagon did not clinically affect the effectiveness of combination therapy. In addition, the change of urinary albumin excretion (ΔUAE) was negatively correlated with systolic blood pressure and HbA1c levels at baseline and positively correlated with the change of systolic blood pressure (ΔsBP) in univariate analysis. Furthermore, in multivariate analysis, only ΔsBP was the independent factor associated with ΔUAE. Taken together, canagliflozin as add-on therapy to teneligliptin improves glycemic control in a Δglucagon-independent manner and reduces UAE in a ΔsBP-dependent manner in Japanese subjects with T2DM.http://dx.doi.org/10.1155/2020/4861681 |
| spellingShingle | Yoshiro Fushimi Atsushi Obata Junpei Sanada Yuichiro Iwamoto Akiko Mashiko Megumi Horiya Akiko Mizoguchi-Tomita Momoyo Nishioka Yuki Kan Tomoe Kinoshita Seizo Okauchi Hidenori Hirukawa Kenji Kohara Fuminori Tatsumi Masashi Shimoda Shuhei Nakanishi Tomoatsu Mune Kohei Kaku Hideaki Kaneto Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study Journal of Diabetes Research |
| title | Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study |
| title_full | Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study |
| title_fullStr | Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study |
| title_full_unstemmed | Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study |
| title_short | Effect of Combination Therapy of Canagliflozin Added to Teneligliptin Monotherapy in Japanese Subjects with Type 2 Diabetes Mellitus: A Retrospective Study |
| title_sort | effect of combination therapy of canagliflozin added to teneligliptin monotherapy in japanese subjects with type 2 diabetes mellitus a retrospective study |
| url | http://dx.doi.org/10.1155/2020/4861681 |
| work_keys_str_mv | AT yoshirofushimi effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT atsushiobata effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT junpeisanada effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT yuichiroiwamoto effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT akikomashiko effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT megumihoriya effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT akikomizoguchitomita effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT momoyonishioka effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT yukikan effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT tomoekinoshita effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT seizookauchi effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT hidenorihirukawa effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT kenjikohara effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT fuminoritatsumi effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT masashishimoda effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT shuheinakanishi effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT tomoatsumune effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT koheikaku effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy AT hideakikaneto effectofcombinationtherapyofcanagliflozinaddedtoteneligliptinmonotherapyinjapanesesubjectswithtype2diabetesmellitusaretrospectivestudy |